- Membership & Community
Publications & News
News & Other Media
The Physiologist Magazine
- January 2020
- March 2020
- May 2020
- May 2020
- July 2020
- Mentoring Forum
- Find Us on Social Media
Meetings & Events
- Experimental Biology
- Integrative Physiology of Exercise
- Related Meetings
- Guidelines for Physiology In Focus Conferences
- Conference Policies
- Conference Proceedings
- Submit a Conference Proposal
Past APS Conferences
- APS/ASN Control of Renal Function in Health and Disease Conference
- Interface of Mathematical Models and Experimental Biology: Role of the Microvasculature Conference
- Aldosterone and ENaC in Health and Disease: The Kidney and Beyond Conference
- APS Institute on Teaching and Learning
- Career & Professional Development
- Meetings & Events
Advocacy & Resources
- Policy & Advocacy
Teaching & Learning Resources
- Educator Resources
- Trainee Resources
- Student Resources
- COVID-19 Resources
APS Graduate Physiology & Biomedical Science Catalog
- Case Western Reserve University – School of Medicine
- Louisiana State University Health Sciences Center
- Mayo Clinic Graduate School of Biomedical Sciences
- Medical College of Wisconsin
- The University of Arizona
- The University of Iowa
- The University of Mississippi Medical Center
- University of California, Davis
- University of Delaware
- University of Georgia College of Veterinary Medicine
- University of Minnesota
- University of Nebraska Medical Center
- University of Texas Health Science Center
- Wayne State University
- West Virginia University Health Sciences Center
- Physiology Department Catalog Submission Form
- Diversity & Inclusion Resources
- About APS
Review encourages medical personnel to develop personalized treatment based on patient’s pathophysiology
Rockville, Md. (June 11, 2020)—A new review details three distinct phases of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, and urges medical professionals to consider an individualized treatment approach based on the disease phases and each patient’s symptoms. The review is published ahead of print in Physiological Reviews.
SARS-CoV-2, the novel coronavirus that causes COVID-19, is transmitted through droplets expelled from an infected person’s nose or mouth when they cough, sneeze or, in some cases, talk. Three distinct phases of COVID-19 infection have been observed in some people who test positive for the disease and have variable degrees of symptoms. Each phase is characterized by a different type of pathophysiological interaction with the virus.
During the early infection phase (Phase 1), the virus multiplies inside the body and is likely to cause mild symptoms that may be confused with a common cold or flu. The second phase is the pulmonary phase (Phase 2), when the immune system becomes strongly affected by infection and leads to primarily respiratory symptoms such as persistent cough, shortness of breath and low oxygen levels. Problems with blood clotting—especially with the formation of blood clots—may be predominant in Phase 2. The third, hyperinflammatory phase (Phase 3), occurs when a hyperactivated immune system may cause injury to the heart, kidneys and other organs. A “cytokine storm”—where the body attacks its own tissues—may occur in this phase. While there may be overlap among the three stages of disease, the review authors stress that it is crucial to recognize each stage in order to tailor treatment to the patient.
Many of the drugs used to treat people with COVID-19 are still being investigated for safety and effectiveness. The reviewers encourage researchers to evaluate these experimental treatments based on the specific disease phase they are being prescribed for, along with what is happening in the body as COVID-19 progresses. Drawing on experience treating patients in Italy, one of the hardest-hit countries during the earliest days of the pandemic, the researchers suggest medical professionals choose a personalized treatment plan with the following medications and treatments:
- Plasma containing antibodies from recovered COVID-19 patients (i.e., hyperimmune plasma), which has been found to reduce the amount of live virus (viral load) in the early infection phase.
- Antiviral drugs, including remdesivir, which have helped interrupt viral replication in Phase 1 and may continue to be beneficial in Phase 2.
- Tissue plasminogen activator (tPA). A drug used to treat stroke, tPA breaks up blood clots that may occur during Phase 2.
- Inflammation-fighting medications, including corticosteroids, tocilizumab and sarilumab. These may help reduce system-wide inflammation in Phases 2 and 3.
- The anticoagulant (anti-clotting drug) heparin is important during any stage of the disease to prevent blood clots in blood vessels and capillaries (micro- and macro-vascular thrombosis).
Although to date, there are no drugs proven to treat COVID-19, research is progressing rapidly. “We are now entering a new era of the pandemic, with many ongoing [randomized controlled trials] aimed at identifying patient-tailored drugs, and drugs better suited to the specific phase of the disease with improved precision,” the authors wrote. The scientific community is “making a tremendous effort to support an unprecedented number of pathophysiological studies and clinical trials to face this highly unexpected pandemic.”
Read the full article, “SARS-CoV-2 and COVID-19: between pathophysiology complexity and therapeutic uncertainty,” published ahead of print in Physiological Reviews.
Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents 9,000 members and publishes 16 peer-reviewed journals with a worldwide readership.
- COVID-19 Resources Archive
- Same Receptor, Different Effect: Research Uncovers New Sex-specific Factor in CV Disease
- Potatoes Are as Effective as Carbohydrate Gels as Fuel Source for Athletes
- More Sleep May Help Teens with ADHD Focus and Organize
- Pairing New Medications Could Offer Hope to Heart Disease Patients
- Researchers Discover New Pathway for Improving Metabolic Health
- Too Hot for Comfort: the Physiological Dangers of Extreme Heat